Methods: A cross-sectional behavioral, clinical, and molecular biological study of 200 women, ages 18-58 years old, who self-referred for gynecological care to Hospital de la Familia, in Ciudad Juárez, Mexico was conducted during a specified 9-month time period. Seroreactivity to HPV was detected by use of the Luminex low-density suspension array and HPV genotyping was conducted by use of the linear array test.
Results: Overall, the prevalence of HPV seropositivity was 44% while the HPV DNA positivity was 22%. In general, seroprevalence with high-risk HPV was 36.9% and multi-HPV exposure was 24.5%. The most commonly detected HPV types were HPV 58 (15.5%), HPV 35 (15.0%), HPV 31 (13.0%), HPV 16 (12.0%), and HPV 52 (10.4%). Additionally, the seropositivity to certain HPV high-risk types was strongly and significantly associated with certain behavioral/lifestyle risk factors such as low family weekly income, alcohol consumption, tobacco use, oral contraceptive use, number of sex partners within the last year, number of lifetime sex partners, and history of STDs.
Conclusion: The high prevalence of HPV 58 and HPV 35 among participants suggests a need for inclusion of multiple HPV types in a vaccine designed to prevent the majority of cervical cancer lesions observed in Ciudad Juárez, Mexico.
Learning Objectives:
• Describe the level of prevalence of the oncogenic and non-oncogenic HPV types in the US-Mexico border city of Ciudad Juárez, Mexico.
• Determine the correlation between HPV seroposistivity and the commonly used clinincal diagnostic criteria of Pap and Colposcopy examination and staging.
• Identify behavioral/lifestyle risk factors associated with an increased risk of HPV infection among women residing in Ciudad Juárez, Mexico.
Keywords: Cancer Screening, Latino Health
Qualified on the content I am responsible for because: I'm the primary investigator.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: Women's Caucus
![[ Visit Client Website ]](images/banner.gif)